Association between hypoglycemia and dementia in patients with diabetes: a systematic review and meta-analysis of 1.4 million patients
- PMID: 35164844
- PMCID: PMC8842524
- DOI: 10.1186/s13098-022-00799-9
Association between hypoglycemia and dementia in patients with diabetes: a systematic review and meta-analysis of 1.4 million patients
Abstract
Background: Diabetes mellitus (DM) is known to be a risk factor for dementia. However, it is unclear if hypoglycemic events play a role in the risk of dementia. We aimed to systematically review evidence on the risk of dementia in DM patients based on prior hypoglycemic events.
Methods: PubMed, Embase, ScienceDirect, CENTRAL, and Google Scholar databases were searched till 15th November 2021 for cohort studies assessing the risk of dementia based on prior hypoglycemic events in DM patients. Adjusted data were pooled in a random-effects model.
Results: Ten studies with a total of 1,407,643 patients were included. Pooled analysis of all ten studies indicated that hypoglycemic episodes were associated with a statistically significant increase in the risk of dementia in DM patients as compared to those not experiencing hypoglycemic episodes (HR: 1.44 95% CI: 1.26, 1.65 I2 = 89% p < 0.00001). The results did not change on the exclusion of any study. Sub-group analysis based on the study population, type of study, adjustment for glycated hemoglobin, gender, and the number of hypoglycemic episodes also presented similar results.
Conclusions: Evidence from observational studies with a large sample size indicates that DM patients with hypoglycemic episodes are at increased risk of dementia. Anti-hyperglycemic drugs should be adequately tailored in these patients to avoid the risk of dementia.
Keywords: Complication; Dementia; Diabetes; Hypoglycemia.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Meta-Analysis: Association Between Hypoglycemia and Serious Adverse Events in Older Patients Treated With Glucose-Lowering Agents.Front Endocrinol (Lausanne). 2021 Mar 8;12:571568. doi: 10.3389/fendo.2021.571568. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33763024 Free PMC article.
-
Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis.BMJ Open Diabetes Res Care. 2018 Nov 16;6(1):e000563. doi: 10.1136/bmjdrc-2018-000563. eCollection 2018. BMJ Open Diabetes Res Care. 2018. PMID: 30487973 Free PMC article.
-
Hypoglycemia is associated with dementia in elderly patients with type 2 diabetes mellitus: An analysis based on the Korea National Diabetes Program Cohort.Diabetes Res Clin Pract. 2016 Dec;122:54-61. doi: 10.1016/j.diabres.2016.09.027. Epub 2016 Oct 8. Diabetes Res Clin Pract. 2016. PMID: 27810686
-
Association of Type 1 Diabetes and Hypoglycemic and Hyperglycemic Events and Risk of Dementia.Neurology. 2021 Jul 19;97(3):e275-e283. doi: 10.1212/WNL.0000000000012243. Neurology. 2021. PMID: 34078717 Free PMC article.
-
Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis.Diabetes Ther. 2019 Jun;10(3):835-852. doi: 10.1007/s13300-019-0624-4. Epub 2019 Apr 24. Diabetes Ther. 2019. PMID: 31020539 Free PMC article. Review.
Cited by
-
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.Circulation. 2024 Feb 20;149(8):e347-e913. doi: 10.1161/CIR.0000000000001209. Epub 2024 Jan 24. Circulation. 2024. PMID: 38264914 Free PMC article. Review.
-
Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists.Theranostics. 2023 Sep 4;13(14):4872-4884. doi: 10.7150/thno.86831. eCollection 2023. Theranostics. 2023. PMID: 37771773 Free PMC article. Review.
-
Exploring the interplay of glucose metabolism, insulin resistance, and neurodegenerative pathologies: insights from streptozotocin and hypoglycaemic in vitro models.J Neural Transm (Vienna). 2025 Feb 11. doi: 10.1007/s00702-025-02891-6. Online ahead of print. J Neural Transm (Vienna). 2025. PMID: 39932549 Review.
-
Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study.EClinicalMedicine. 2024 Jun 20;73:102689. doi: 10.1016/j.eclinm.2024.102689. eCollection 2024 Jul. EClinicalMedicine. 2024. PMID: 39429814 Free PMC article.
-
Effects of Peroxisome Proliferator-Activated Receptor-Gamma Agonists on Cognitive Function: A Systematic Review and Meta-Analysis.Biomedicines. 2023 Jan 18;11(2):246. doi: 10.3390/biomedicines11020246. Biomedicines. 2023. PMID: 36830783 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources